Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

IgG Levels and Wear Off Reflect Administration and Outcome
Carol L. Koski, MD
GBS/CIDP Foundation International
5:51 MIN
  • CIDP
  • GBS
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
DOWNLOAD PDF
Incidence of GBS and CIDP Following Influenza Vaccination
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
25:18 MIN
  • CIDP
  • GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

DOWNLOAD PDF
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
3:00 MIN
  • CIDP
  • MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

DOWNLOAD PDF
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
Jeffrey A. Allen, MD
University of Minnesota
12:50 MIN
  • CIDP
  • MMN
Review options for individualizing treatment and tools used to assess IgG performance
DOWNLOAD PDF
NOW PLAYING
5:51
IgG Levels and Wear Off Reflect Administration and Outcome
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
NOW PLAYING
25:18
Incidence of GBS and CIDP Following Influenza Vaccination

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

NOW PLAYING
3:00
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

NOW PLAYING
12:50
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
Review options for individualizing treatment and tools used to assess IgG performance

Our Experts on CIDP

Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
Peter Van den Bergh, MD PhD
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
  • CIDP

Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • CIDP
  • GBS
  • MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
  • CIDP
  • MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

  • CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 396 KB
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-...
PDF | 3.8 MB
Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 421 KB
Wear-Off in IVIG and What it Means in Clinical Practice
PDF | 
Back to Top